U.S., June 18 -- ClinicalTrials.gov registry received information related to the study (NCT07655375) titled 'Study Evaluating the Effect of UCB8600 on Mast Cell Activation in the Human Gut' on June 12.
Brief Summary: Study evaluating the effect of UCB8600 on mast cell activation in the human gut:
IBS is a disease characterized by abdominal pain and a change in stool. Treatment is limited to an adapted life style, dietary changes and medication to lessen cramps (spasmolytica), all of which have seen limited to no clinical success.
Recently, we were able to demonstrate that mast cells play an active role in IBS symptoms. More specifically, they set histamine free when activated which heightens nerve sensitivity in the intestines which prob...